Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mabjeesh, N. J.
Right arrow Articles by Zhong, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mabjeesh, N. J.
Right arrow Articles by Zhong, H.
[Cancer Research 62, 2478-2482, May 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Geldanamycin Induces Degradation of Hypoxia-inducible Factor 1{alpha} Protein via the Proteosome Pathway in Prostate Cancer Cells1

Nicola J. Mabjeesh, Dawn E. Post, Margaret T. Willard, Balveen Kaur, Erwin G. Van Meir, Jonathan W. Simons2 and Hua Zhong

Winship Cancer Institute, Departments of Hematology and Oncology and Neurosurgery, Emory University School of Medicine, Atlanta, Georgia 30322

Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factorcomposed of {alpha} and ß subunits. HIF-1 is critically involved in cellular responses to hypoxia, glycolysis, and angiogenesis. Here, we show that treatment of prostate cancer PC-3 and LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, induced degradation of HIF-1{alpha} protein in a dose- and time-dependent manner under both normoxia and hypoxia. This inhibition was also shown in other common cancer types tested. Rapid degradation of nuclear HIF-1{alpha} protein levels was accompanied by respective inhibition in HIF-1{alpha} functional transcription activity of VEGF. No difference between HIF-1{alpha} mRNA levels before or after geldanamycin treatment was found. Moreover, [35S]methionine pulse-chase analysis revealed that HIF-1{alpha} protein half-life was markedly decreased in the presence of geldanamycin compared with that in control. The geldanamycin-induced degradation of HIF-1{alpha} was reversed by proteosome inhibitors lactacystin and MG-132. We conclude that geldanamycin induces reduction of HIF-1{alpha} levels and its downstream transcriptional activity by accelerating protein degradation independent of O2 tension. Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-aminogeldanamycin, are excellent candidates as small molecule drug inhibitors of HIF-1 overexpression in cancer cells.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
X. Cao, M. Bloomston, T. Zhang, W. L. Frankel, G. Jia, B. Wang, N. C. Hall, R. M. Koch, H. Cheng, M. V. Knopp, et al.
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
Clin. Cancer Res., March 15, 2008; 14(6): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Y. Koh, T. Spivak-Kroizman, S. Venturini, S. Welsh, R. R. Williams, D. L. Kirkpatrick, and G. Powis
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1{alpha}
Mol. Cancer Ther., January 1, 2008; 7(1): 90 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Chandarlapaty, A. Sawai, Q. Ye, A. Scott, M. Silinski, K. Huang, P. Fadden, J. Partdrige, S. Hall, P. Steed, et al.
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers
Clin. Cancer Res., January 1, 2008; 14(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Rapisarda and G. Melillo
HIF-1 Inhibitors: Novel Opportunities for Cancer Therapy
ASCO Educational Book, January 1, 2008; 2008(1): 543 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. H. Baek, Y. V. Liu, K. R. McDonald, J. B. Wesley, H. Zhang, and G. L. Semenza
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1{alpha} (HIF-1{alpha}) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1{alpha}
J. Biol. Chem., November 16, 2007; 282(46): 33358 - 33366.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Lang, C. Moser, A. Gaumann, D. Klein, G. Glockzin, F. C. Popp, M. H. Dahlke, P. Piso, H. J. Schlitt, E. K. Geissler, et al.
Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1{alpha} Autocrine Loop, and Reduces Orthotopic Tumor Growth
Clin. Cancer Res., November 1, 2007; 13(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Mizukami, Y. Kohgo, and D. C. Chung
Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis
Clin. Cancer Res., October 1, 2007; 13(19): 5670 - 5674.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. D.W. van der Bilt, M. E. Soeters, A. M.M.J. Duyverman, M. W. Nijkamp, P. O. Witteveen, P. J. van Diest, O. Kranenburg, and I. H.M. Borel Rinkes
Perinecrotic Hypoxia Contributes to Ischemia/Reperfusion-Accelerated Outgrowth of Colorectal Micrometastases
Am. J. Pathol., April 1, 2007; 170(4): 1379 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Lang, D. Klein, C. Moser, A. Gaumann, G. Glockzin, M. H. Dahlke, W. Dietmaier, U. Bolder, H. J. Schlitt, E. K. Geissler, et al.
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo
Mol. Cancer Ther., March 1, 2007; 6(3): 1123 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo
Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221
Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Lang, G. W. Caldwell, J. Li, G. C. Leo, W. J. Jones, and J. A. Masucci
Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive versus Oxidative Metabolism and Implications
Drug Metab. Dispos., January 1, 2007; 35(1): 21 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Iliopoulos
Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets
J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Melillo
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Mol. Cancer Res., September 1, 2006; 4(9): 601 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K.-S. Kim, S. Sengupta, M. Berk, Y.-G. Kwak, P. F. Escobar, J. Belinson, S. C. Mok, and Y. Xu
Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo
Cancer Res., August 15, 2006; 66(16): 7983 - 7990.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Kaluz, M. Kaluzova, and E. J. Stanbridge
Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1{alpha} C-Terminal Activation Domain
Mol. Cell. Biol., August 1, 2006; 26(15): 5895 - 5907.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. G. Kiang, P. D. Bowman, X. Lu, Y. Li, X. Z. Ding, B. Zhao, Y.-T. Juang, J. L. Atkins, and G. C. Tsokos
Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyruvate dehydrogenase
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G117 - G127.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
C. R. Barker, A. V. McNamara, S. A. Rackstraw, D. E. Nelson, M. R. White, A. J. M. Watson, and J. R. Jenkins
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
Nucleic Acids Res., February 16, 2006; 34(4): 1148 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Amir, R. Wang, H. Matzkin, J. W. Simons, and N. J. Mabjeesh
MSF-A Interacts with Hypoxia-Inducible Factor-1{alpha} and Augments Hypoxia-Inducible Factor Transcriptional Activation to Affect Tumorigenicity and Angiogenesis
Cancer Res., January 15, 2006; 66(2): 856 - 866.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. O. Ibrahim, T. Hahn, C. Franke, D. P. Stiehl, R. Wirthner, R. H. Wenger, and D. M. Katschinski
Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors
Cancer Res., December 1, 2005; 65(23): 11094 - 11100.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Kong, E. J. Park, A. G. Stephen, M. Calvani, J. H. Cardellina, A. Monks, R. J. Fisher, R. H. Shoemaker, and G. Melillo
Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity
Cancer Res., October 1, 2005; 65(19): 9047 - 9055.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J.-Y. Han, S. H. Oh, F. Morgillo, J. N. Myers, E. Kim, W. K. Hong, and H.-Y. Lee
Hypoxia-inducible Factor 1{alpha} and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
J Natl Cancer Inst, September 7, 2005; 97(17): 1272 - 1286.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T Gaber, R Dziurla, R Tripmacher, G R Burmester, and F Buttgereit
Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!
Ann Rheum Dis, July 1, 2005; 64(7): 971 - 980.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Grem, G. Morrison, X.-D. Guo, E. Agnew, C. H. Takimoto, R. Thomas, E. Szabo, L. Grochow, F. Grollman, J. M. Hamilton, et al.
Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors
J. Clin. Oncol., March 20, 2005; 23(9): 1885 - 1893.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. Sun and J. K. Liao
Induction of Angiogenesis by Heat Shock Protein 90 Mediated by Protein Kinase Akt and Endothelial Nitric Oxide Synthase
Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2238 - 2244.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Biol.Home page
T. Acker and H. Acker
Cellular oxygen sensing need in CNS function: physiological and pathological implications
J. Exp. Biol., August 15, 2004; 207(18): 3171 - 3188.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. G. Kiang, P. D. Bowman, B. W. Wu, N. Hampton, A. G. Kiang, B. Zhao, Y.-T. Juang, J. L. Atkins, and G. C. Tsokos
Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70
J Appl Physiol, August 1, 2004; 97(2): 564 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Kaur, D. Belotti, A. M. Burger, K. Fisher-Nielson, P. Borsotti, E. Riccardi, J. Thillainathan, M. Hollingshead, E. A. Sausville, and R. Giavazzi
Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator
Clin. Cancer Res., July 15, 2004; 10(14): 4813 - 4821.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Powis and L. Kirkpatrick
Hypoxia inducible factor-1{alpha} as a cancer drug target
Mol. Cancer Ther., May 1, 2004; 3(5): 647 - 654.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Isaacs, Y.-J. Jung, and L. Neckers
Aryl Hydrocarbon Nuclear Translocator (ARNT) Promotes Oxygen-independent Stabilization of Hypoxia-inducible Factor-1{alpha} by Modulating an Hsp90-dependent Regulatory Pathway
J. Biol. Chem., April 16, 2004; 279(16): 16128 - 16135.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Zhou, T. Schmid, R. Frank, and B. Brune
PI3K/Akt Is Required for Heat Shock Proteins to Protect Hypoxia-inducible Factor 1{alpha} from pVHL-independent Degradation
J. Biol. Chem., April 2, 2004; 279(14): 13506 - 13513.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. Hopfl, O. Ogunshola, and M. Gassmann
HIFs and tumors--causes and consequences
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y.-H. Li, P.-Z. Tao, Y.-Z. Liu, and J.-D. Jiang
Geldanamycin, a Ligand of Heat Shock Protein 90, Inhibits the Replication of Herpes Simplex Virus Type 1 In Vitro
Antimicrob. Agents Chemother., March 1, 2004; 48(3): 867 - 872.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Jiang, D. Cyr, R. W. Babbitt, W. C. Sessa, and C. Patterson
Chaperone-dependent Regulation of Endothelial Nitric-oxide Synthase Intracellular Trafficking by the Co-chaperone/Ubiquitin Ligase CHIP
J. Biol. Chem., December 5, 2003; 278(49): 49332 - 49341.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. de Candia, D. B. Solit, D. Giri, E. Brogi, P. M. Siegel, A. B. Olshen, W. J. Muller, N. Rosen, and R. Benezra
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors
PNAS, October 14, 2003; 100(21): 12337 - 12342.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. R. Macpherson, S. S.W. Ng, S. L. Forbes, G. Melillo, T. Karpova, J. McNally, T. P. Conrads, T. D. Veenstra, A. Martinez, F. Cuttitta, et al.
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay
Mol. Cancer Ther., September 1, 2003; 2(9): 845 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. T. Palayoor, P. J. Tofilon, and C. N. Coleman
Ibuprofen-mediated Reduction of Hypoxia-inducible Factors HIF-1{alpha} and HIF-2{alpha} in Prostate Cancer Cells
Clin. Cancer Res., August 1, 2003; 9(8): 3150 - 3157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. Mabjeesh, M. T. Willard, C. E. Frederickson, H. Zhong, and J. W. Simons
Androgens Stimulate Hypoxia-inducible Factor 1 Activation via Autocrine Loop of Tyrosine Kinase Receptor/Phosphatidylinositol 3'-Kinase/Protein Kinase B in Prostate Cancer Cells
Clin. Cancer Res., July 1, 2003; 9(7): 2416 - 2425.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. R. Welch and K. W. Hunter
A New Member of the Growing Family of Metastasis Suppressors Identified in Prostate Cancer
J Natl Cancer Inst, June 18, 2003; 95(12): 839 - 841.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. E. Huang and H. F. Bunn
Hypoxia-inducible Factor and Its Biomedical Relevance
J. Biol. Chem., May 23, 2003; 278(22): 19575 - 19578.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. Brat and T. B. Mapstone
Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression
Ann Intern Med, April 15, 2003; 138(8): 659 - 668.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. E. Huang, E. A. Pete, M. Schau, J. Milligan, and J. Gu
Leu-574 of HIF-1alpha Is Essential for the von Hippel-Lindau (VHL)-mediated Degradation Pathway
J. Biol. Chem., October 25, 2002; 277(44): 41750 - 41755.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Isaacs, Y.-J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta, and L. M. Neckers
Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative Pathway
J. Biol. Chem., August 9, 2002; 277(33): 29936 - 29944.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.